SCHEMBL23911573

SCHEMBL23911573

CCC(O)c1ccc2c(Cl)ccnc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 2/20 0.41
SMYD3 Q9H7B4 1/20 0.40
PDE2A O00408 1/20 0.37
PDE10A Q9Y233 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
LMNA P02545 2/20 0.37
NR4A2 P43354 2/20 0.35
TLR8 Q9NR97 1/20 0.35
OPRK1 P41145 2/20 0.35
KMT2A Q03164 2/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
MEN1 O00255 1/20 0.35
SOS2 Q07890 1/20 0.35
CYP1A2 P05177 1/20 0.35
KDM4E B2RXH2 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PRNP P04156 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30144745 0.83 OGA (0.46) OGASMYD3LMNANR4A2TLR8
SCHEMBL17541684 0.83 OGA (0.46) OGASMYD3LMNANR4A2TLR8
SCHEMBL17541554 0.78 OGA (0.44) OGASMYD3NR4A2TLR8KMT2A
SCHEMBL3611078 0.77 LMNA (0.44) OGAKDM5BLMNAKMT2AMEN1
SCHEMBL26928427 0.76 ACHE (0.38) PDE2APDE10AKDM5BLMNAKMT2A
SCHEMBL26087032 0.76 OGA (0.42) OGASMYD3NR4A2TLR8KMT2A
SCHEMBL20519349 0.74 RECQL (0.44) PDE2APDE10AKDM5BLMNA
SCHEMBL30107284 0.74 RECQL (0.44) PDE2APDE10AKDM5BLMNA
SCHEMBL6853770 0.72 ALDH1A1 (0.50) OGAPDE10ALMNANR4A2OPRK1
SCHEMBL14047172 0.71 LMNA (0.48) LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 OGA 566/4885SMYD3 3126/4885PDE2A 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.